Davis Polk advised Advanced Accelerator Applications S.A. on its approximately $150 million SEC-registered follow-on offering of American Depositary Shares representing its ordinary shares. Each ADS represents two ordinary shares of AAA. The ADSs are listed on the NASDAQ Global Select Market under the symbol “AAAP.”
Based in Saint Genis Pouilly, France, AAA is a French radiopharmaceutical company founded in 2002 to develop innovative molecular nuclear medicine (MNM) products. AAA’s lead therapeutic product candidate, Lutathera, is a novel MNM compound that AAA is currently developing for the treatment of neuroendocrine tumors, a significant unmet medical need.
The Davis Polk corporate team included partner John G. Crowley and associates Yasin Keshvargar and Martin Oberst. Partner Jacques Naquet-Radiguet and associates Samuel Berrebbi and Stéphane Daniel provided French law advice. The tax team included partner Rachel D. Kleinberg and associate Sam R. Van Peperstraete. The intellectual property and technology team included counsel David R. Bauer and associate Arjun Ravi. Members of the Davis Polk team are based in the New York, Paris and Northern California offices.